This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lustig, S.
Right arrow Articles by Moss, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lustig, S.
Right arrow Articles by Moss, B.

 Previous Article  |  Next Article 

Journal of Virology, November 2005, p. 13454-13462, Vol. 79, No. 21
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.21.13454-13462.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge

Shlomo Lustig ,1,{dagger},{ddagger} Christiana Fogg,1,{dagger} J. Charles Whitbeck,2 Roselyn J. Eisenberg,2 Gary H. Cohen,2 and Bernard Moss1*

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland,1 Schools of Dental and Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania2

Received 6 July 2005/ Accepted 2 August 2005

Previous studies demonstrated that antibodies to live vaccinia virus infection are needed for optimal protection against orthopoxvirus infection. The present report is the first to compare the protective abilities of individual and combinations of specific polyclonal and monoclonal antibodies that target proteins of the intracellular (IMV) and extracellular (EV) forms of vaccinia virus. The antibodies were directed to one IMV membrane protein, L1, and to two outer EV membrane proteins, A33 and B5. In vitro studies showed that the antibodies to L1 neutralized IMV and that the antibodies to A33 and B5 prevented the spread of EV in liquid medium. Prophylactic administration of individual antibodies to BALB/c mice partially protected them against disease following intranasal challenge with lethal doses of vaccinia virus. Combinations of antibodies, particularly anti-L1 and -A33 or -L1 and -B5, provided enhanced protection when administered 1 day before or 2 days after challenge. Furthermore, the protection was superior to that achieved with pooled immune gamma globulin from human volunteers inoculated with live vaccinia virus. In addition, single injections of anti-L1 plus anti-A33 antibodies greatly delayed the deaths of severe combined immunodeficiency mice challenged with vaccinia virus. These studies suggest that antibodies to two or three viral membrane proteins optimally derived from the outer membranes of IMV and EV, may be beneficial for prophylaxis or therapy of orthopoxvirus infections.

* Corresponding author. Mailing address: Laboratory of Viral Diseases, National Institutes of Health, 4 Memorial Dr., MSC 0445, Bethesda, MD 20892-0445. Phone: (301) 496-9869. Fax: (301) 480-1147. E-mail: bmoss{at}nih.gov.

{dagger} S.L. and C.F. contributed equally to this work.

{ddagger} Present address: Department of Infectious Diseases, Israel Institute for Biological Research, P.O. Box 19, 74100 Ness-Ziona, Israel.

Journal of Virology, November 2005, p. 13454-13462, Vol. 79, No. 21
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.21.13454-13462.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Satheshkumar, P. S., Moss, B. (2009). Characterization of a Newly Identified 35-Amino-Acid Component of the Vaccinia Virus Entry/Fusion Complex Conserved in All Chordopoxviruses. J. Virol. 83: 12822-12832 [Abstract] [Full Text]  
  • Benhnia, M. R.-E.-I., McCausland, M. M., Laudenslager, J., Granger, S. W., Rickert, S., Koriazova, L., Tahara, T., Kubo, R. T., Kato, S., Crotty, S. (2009). Heavily Isotype-Dependent Protective Activities of Human Antibodies against Vaccinia Virus Extracellular Virion Antigen B5. J. Virol. 83: 12355-12367 [Abstract] [Full Text]  
  • Bisht, H., Weisberg, A. S., Szajner, P., Moss, B. (2009). Assembly and Disassembly of the Capsid-Like External Scaffold of Immature Virions during Vaccinia Virus Morphogenesis. J. Virol. 83: 9140-9150 [Abstract] [Full Text]  
  • Benhnia, M. R.-E.-I., McCausland, M. M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koriazova, L., Kubo, R., Kato, S., Crotty, S. (2009). Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement. J. Virol. 83: 1201-1215 [Abstract] [Full Text]  
  • Midgley, C. M., Putz, M. M., Weber, J. N., Smith, G. L. (2008). Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89: 2992-2997 [Abstract] [Full Text]  
  • Salek-Ardakani, S., Moutaftsi, M., Crotty, S., Sette, A., Croft, M. (2008). OX40 Drives Protective Vaccinia Virus-Specific CD8 T Cells. J. Immunol. 181: 7969-7976 [Abstract] [Full Text]  
  • Fogg, C. N., Americo, J. L., Earl, P. L., Resch, W., Aldaz-Carroll, L., Eisenberg, R. J., Cohen, G. H., Moss, B. (2008). Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge. J. Virol. 82: 8022-8029 [Abstract] [Full Text]  
  • Kaufman, D. R., Goudsmit, J., Holterman, L., Ewald, B. A., Denholtz, M., Devoy, C., Giri, A., Grandpre, L. E., Heraud, J.-M., Franchini, G., Seaman, M. S., Havenga, M. J. E., Barouch, D. H. (2008). Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice. J. Virol. 82: 6829-6837 [Abstract] [Full Text]  
  • Benhnia, M. R.-E.-I., McCausland, M. M., Su, H.-P., Singh, K., Hoffmann, J., Davies, D. H., Felgner, P. L., Head, S., Sette, A., Garboczi, D. N., Crotty, S. (2008). Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine. J. Virol. 82: 3751-3768 [Abstract] [Full Text]  
  • Chen, Z., Earl, P., Americo, J., Damon, I., Smith, S. K., Yu, F., Sebrell, A., Emerson, S., Cohen, G., Eisenberg, R. J., Gorshkova, I., Schuck, P., Satterfield, W., Moss, B., Purcell, R. (2007). Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model. J. Virol. 81: 8989-8995 [Abstract] [Full Text]  
  • Aldaz-Carroll, L., Xiao, Y., Whitbeck, J. C., de Leon, M. P., Lou, H., Kim, M., Yu, J., Reinherz, E. L., Isaacs, S. N., Eisenberg, R. J., Cohen, G. H. (2007). Major Neutralizing Sites on Vaccinia Virus Glycoprotein B5 Are Exposed Differently on Variola Virus Ortholog B6. J. Virol. 81: 8131-8139 [Abstract] [Full Text]  
  • Garcia, A. D., Meseda, C. A., Mayer, A. E., Kumar, A., Merchlinsky, M., Weir, J. P. (2007). Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines. CVI 14: 1032-1044 [Abstract] [Full Text]  
  • Jing, L., Chong, T. M., Byrd, B., McClurkan, C. L., Huang, J., Story, B. T., Dunkley, K. M., Aldaz-Carroll, L., Eisenberg, R. J., Cohen, G. H., Kwok, W. W., Sette, A., Koelle, D. M. (2007). Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus. J. Immunol. 178: 6374-6386 [Abstract] [Full Text]  
  • Tang, J., Murtadha, M., Schnell, M., Eisenlohr, L. C., Hooper, J., Flomenberg, P. (2006). Human T-cell responses to vaccinia virus envelope proteins.. J. Virol. 80: 10010-10020 [Abstract] [Full Text]  
  • Panchanathan, V., Chaudhri, G., Karupiah, G. (2006). Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell Function.. J. Virol. 80: 6333-6338 [Abstract] [Full Text]  
  • Chen, Z., Earl, P., Americo, J., Damon, I., Smith, S. K., Zhou, Y.-H., Yu, F., Sebrell, A., Emerson, S., Cohen, G., Eisenberg, R. J., Svitel, J., Schuck, P., Satterfield, W., Moss, B., Purcell, R. (2006). Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA 103: 1882-1887 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»